Study of Neoadjuvant Docetaxel and Cyclophosphamide in Locally Advanced or Node Positive Primary Breast Cancer With Companion Pharmacokinetic and Pharmacogenomic Analyses

• Status: Completed
• Trial end date: 2015-10-20

Summary

Primary

The purpose of this study is to evaluate tumour pathological complete response rate after six cycles of neoadjuvant docetaxel and cyclophosphamide in an Asian population.

Secondary

To assess:

1. Pharmacokinetics (PK) and pharmacogenomics (PG) of docetaxel cyclophosphamide in Asian patients,

2. Safety and toxicity of docetaxel cyclophosphamide in Asian patients, and

3. To determine efficacy of short course (3 days) filgrastim in primary and secondary prophylaxis against febrile neutropenia in patients receiving docetaxel and cyclophosphamide.

• Phase: Phase 2

Details

• Lead Sponsor: National Cancer Centre, Singapore
• Treatments: Cyclophosphamide; Docetaxel